Inflammation Clinical Trial
Official title:
Influence of Ingesting a Flavonoid-rich Supplement on the Human Metabolome and Concentration of Urine Phenolics
This study will measure the effect of ingesting a flavonoid-rich supplement on various biomarkers in overweight/obese women during a 12-week period. The flavonoid-rich supplement contains a mixture of flavonoids including quercetin, catechins from green tea extract, and anthocyanins from bilberry extract, and other food components that facilitate flavonoid bioactivity including fish oil, caffeine, and vitamin C.
1. The primary objective of this study is to evaluate the effect of ingesting a
flavonoid-rich supplement on total urine polyphenol concentration and shifts in blood
metabolites related to flavonoid intake in healthy but overweight/obese
community-dwelling adults.
2. Secondary objectives are to determine related effects on measures of inflammation and
oxidative stress. Studies are mixed regarding the influence of flavonoid supplements on
traditional biomarkers for inflammation and oxidative stress, and metabolite shifts
from the metabolomics measurements may provide better insights. Chemistry profiles and
symptom logs will be compared pre- and post-study between groups to confirm prior
safety data collected on human participants.
Hypothesis: Subjects randomized to ingestion of the flavonoid-rich supplement compared to
placebo will experience an increase in total urine polyphenols concentrations and shifts in
blood metabolites related to increased flavonoid metabolism. Secondarily, subjects ingesting
the flavonoid-rich supplement will experience a decrease in systemic inflammation and
oxidative stress.
BASELINE TESTING (ASU-NCRC HUMAN PERFORMANCE LAB):
A. One week before the start of the study, subjects will report to the ASU-NCRC Human
Performance Lab, be oriented to the study, and provide voluntary consent. Subjects will fill
in a medical health questionnaire to verify medical history and lifestyle habits. Subjects
must agree to maintain normal dietary and physical activity patterns during the 12-week
intervention, and not make formal attempts to lose body weight. All other subject inclusion
and exclusion criteria must be maintained during the study. Subjects will be instructed on
how to record all food intake during a 3-day period prior to the start of the study
(Thursday, Friday, and Sunday).
Subjects will be instructed on how to collect urine for 24-hours during the day just before
the study starts. Urine collection guidelines:
- You should collect every drop of urine during each 24-hour period. It does not matter
how much or little urine is passed each time, as long as every drop is collected.
- Begin the urine collection in the morning after you wake up, after you have emptied
your bladder for the first time.
- Urinate (empty the bladder) for the first time and flush it down the toilet. Note the
exact time (eg, 6:15 AM). You will begin the urine collection at this time.
- Collect every drop of urine during the day and night in an empty collection bottle.
Store the bottle in the refrigerator. Be sure to collect any urine passed during bowel
movements.
- Finish by collecting the first urine passed the next morning, adding it to the
collection bottle. This should be within ten minutes before or after the time of the
first morning void on the first day (which was flushed). In this example, you would try
to void between 6:05 and 6:25 on the second day. If you need to urinate one hour before
the final collection time, drink a full glass of water so that you can void again at
the appropriate time. If you have to urinate 20 minutes before, try to hold the urine
until the proper time.
- Please note the exact time of the final collection.
B. On the first day of the study, subjects will return to the lab in a fasted state (9 or
more hours with no food or beverage other than water) and turn in the 3-day food record and
the 24-h urine collection sample. Height, body weight, and percent body fat (seca BIA scale)
will be measured. Blood samples will be collected from an antecubital vein with subjects in
the seated position by trained phlebotomists. Each blood sample will not exceed 40 ml (2.7
tablespoons). Subjects will also record responses to a 4-week retrospective symptom log.
Subjects will be given flavonoid or placebo supplements for the first 4-week period, and
ingest the first two supplements in the lab under supervision.
12-WEEK INTERVENTION: Subjects (N=110) will be randomized to the flavonoid supplement or
placebo supplement groups for 12 weeks (thus two independent groups run in parallel with 55
subjects). Supplements will be administered in a double-blinded manner, with the code held
by Reoxcyn Discoveries Group until the end of the study. The goal is for N=100 subjects to
complete all phases of the study. Subjects will ingest two supplement supplements each day
of the study, one before breakfast, and the second one before lunch.
Subjects will report to the Human Performance Lab at the 4- and 12-week time points in an
overnight-fasted state and repeat all baseline measurements (including the 3-day food record
and 24-h urine collection). The 4-week retrospective symptom logs will be filled in at
pre-study, 4, 8, and 12 weeks (with the 8-week log administered via email). Subjects will be
given an 8-weeks supply of the supplement after completing the 4-week lab session.
SUPPLEMENT INFORMATION:
The flavonoid-rich supplement contains a mixture of flavonoids from green tea and bilberry
extracts, and quercetin. The supplement also contains food components that boost flavonoid
benefits in the body including fish oil, caffeine, and vitamin C.
The daily dose will be 4 flavonoid tablets (two before breakfast, two before lunch).
Here is a detailed summary of the ingredients of the flavonoid-rich supplement (4 tablets
per day):
Supplement Facts Serving size: 4 Tablets Servings per container: 30 Amount per Serving %
Daily Value Calories 50 Total Carbohydrate 12 g 4% Sugars 10 g Vitamin C (as Ascorbyl
Palmitate) 100 mg 167% Wild Bilberry Fruit Extract (std. min. 25% Total Anthocyanins) 156 mg
** Green Tea Leaf Extract 180 mg ** Quercetin 100 mg ** Natural Caffeine (from Coffea
arabica Bean) 100 mg ** NovoOmega® Omega-3 F30 Powder (Std. 30% Omega-3 Fatty Acids
(Eicosapentaenoic Acid and Docosahexaenoic Acid)) 200 mg ** * Percent Daily Values are based
on a 2,000 calorie diet
** Daily Value not Established Other Ingredients: Sugar, Natural & Artificial Flavor,
Dextrose, Cellulose Gum, Sucralose, Bamboo Whole Plant Extract, Guar Gum, Xanthan Gum,
Citric Acid, Malic Acid, L-Tartaric Acid Contains Fish.
In general, the flavonoid-rich chewable tablets (4 per day) will provide the equivalent
quantity of flavonoids as found in 10 apples, one cup of green tea, and one-fourth cup of
bilberries. Consuming 4 tablets per day will add approximately 50% more of the beneficial
polyphenols typically consumed by adults.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03995979 -
Inflammation and Protein Restriction
|
N/A | |
Completed |
NCT03255187 -
Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT03577223 -
Egg Effects on the Immunomodulatory Properties of HDL
|
N/A | |
Completed |
NCT04383561 -
Relationship Between LRG and Periodontal Disease
|
N/A | |
Active, not recruiting |
NCT03622632 -
Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
|
||
Completed |
NCT06216015 -
Exercise Training and Kidney Transplantation
|
N/A | |
Completed |
NCT04856748 -
Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
|
||
Completed |
NCT05529693 -
Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population
|
N/A | |
Recruiting |
NCT05415397 -
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
|
Phase 3 | |
Recruiting |
NCT05670301 -
Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases
|
N/A | |
Recruiting |
NCT05775731 -
Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
|
||
Recruiting |
NCT04543877 -
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
|
Early Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Completed |
NCT03429920 -
Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors
|
N/A | |
Active, not recruiting |
NCT06065241 -
Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals.
|
N/A | |
Active, not recruiting |
NCT05864352 -
The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
|
||
Completed |
NCT03318731 -
Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males
|
N/A | |
Not yet recruiting |
NCT06134076 -
Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota
|
N/A | |
Not yet recruiting |
NCT05910489 -
Micro and Nanoplastics in Greenhouse Workers: Biomarkers of Exposure and Effect
|